company background image
AVTX

Avalo Therapeutics NasdaqCM:AVTX Stock Report

Last Price

US$4.00

Market Cap

US$37.7m

7D

-18.4%

1Y

-63.9%

Updated

28 Jan, 2023

Data

Company Financials +

Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Mkt Cap: US$37.7m

AVTX Stock Overview

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.

AVTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

New

Notes are coming soon

Avalo Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avalo Therapeutics
Historical stock prices
Current Share PriceUS$4.00
52 Week HighUS$12.60
52 Week LowUS$2.42
Beta1.56
1 Month Change-20.87%
3 Month Change-34.43%
1 Year Change-63.88%
3 Year Change-91.56%
5 Year Change-88.89%
Change since IPO-91.67%

Recent News & Updates

Recent updates

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10
Is Cerecor (NASDAQ:CERC) A Risky Investment?

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10
What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18
Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

How Much Of Cerecor Inc. (NASDAQ:CERC) Do Institutions Own?

Nov 27
How Much Of Cerecor Inc. (NASDAQ:CERC) Do Institutions Own?

Shareholder Returns

AVTXUS BiotechsUS Market
7D-18.4%0.8%2.8%
1Y-63.9%7.1%-9.2%

Return vs Industry: AVTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: AVTX underperformed the US Market which returned -9.7% over the past year.

Price Volatility

Is AVTX's price volatile compared to industry and market?
AVTX volatility
AVTX Average Weekly Movement9.1%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: AVTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AVTX's weekly volatility has decreased from 15% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201143Garry Neilhttps://www.avalotx.com

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis.

Avalo Therapeutics, Inc. Fundamentals Summary

How do Avalo Therapeutics's earnings and revenue compare to its market cap?
AVTX fundamental statistics
Market CapUS$37.66m
Earnings (TTM)-US$50.98m
Revenue (TTM)US$17.37m

2.2x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVTX income statement (TTM)
RevenueUS$17.37m
Cost of RevenueUS$29.46m
Gross Profit-US$12.08m
Other ExpensesUS$38.89m
Earnings-US$50.98m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.41
Gross Margin-69.55%
Net Profit Margin-293.41%
Debt/Equity Ratio-940.1%

How did AVTX perform over the long term?

See historical performance and comparison